Payment overview · 2025
General Payments
$826.38
35 reported records · 11 companies
Healthcare provider profile · identity verified
Tamara Pinkhasova, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1306888490
Verified facts
What the public records show
CMS Open Payments records show Tamara Pinkhasova, MD received $826.38 in general payments during 2025 across 35 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $256.03 | 31.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $221.28 | 26.8% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.74 | 8.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.54 | 7.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.30 | 7.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.42 | 6.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.80 | 3.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.21 | 2.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.25 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.91 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.90 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $826.38 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $221.28 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $221.28 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $142.80 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $93.82 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.74 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.54 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $62.30 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.30 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.42 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.42 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 165 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
165 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 716 | 203 |
| Metformin Hcl | Metformin Hcl | 487 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 444 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 398 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 88 |
| Gabapentin | Gabapentin | 289 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 66 |
| Jardiance | Empagliflozin | 197 | 40 |
| Furosemide | Furosemide | 191 | 48 |
| Lisinopril | Lisinopril | 189 | 47 |
| Simvastatin | Simvastatin | 189 | 49 |
| Losartan Potassium | Losartan Potassium | 187 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 185 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 47 |
| Famotidine | Famotidine | 179 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 48 |
| Omeprazole | Omeprazole | 176 | 50 |
| Farxiga | Dapagliflozin Propanediol | 165 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 161 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 43 |
| Mirtazapine | Mirtazapine | 131 | 28 |
| Ammonium Lactate | Ammonium Lactate | 122 | 36 |
| Carvedilol | Carvedilol | 118 | 28 |
| Valsartan | Valsartan | 117 | 36 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 101 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 97 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 95 | 19 |
| Meloxicam | Meloxicam | 94 | 29 |
| Finasteride | Finasteride | 92 | 30 |
| Ketoconazole | Ketoconazole | 90 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 32 |
| Linzess | Linaclotide | 87 | 15 |
| Ozempic | Semaglutide | 86 | 20 |
| Eliquis | Apixaban | 84 | 17 |
| Prednisone | Prednisone | 84 | 27 |
| Trazodone Hcl | Trazodone Hcl | 82 | 22 |
| Trulicity | Dulaglutide | 82 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 15 |
| Nystatin | Nystatin | 73 | 25 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 72 | 20 |
| Vascepa | Icosapent Ethyl | 71 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 22 |
| Novolog Flexpen | Insulin Aspart | 67 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 65 | 29 |
| Meclizine Hcl | Meclizine Hcl | 65 | 18 |
| Alendronate Sodium | Alendronate Sodium | 64 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 14 |
| Montelukast Sodium | Montelukast Sodium | 60 | 17 |
| Azithromycin | Azithromycin | 59 | 45 |
| Mometasone Furoate | Mometasone Furoate | 57 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | 17 |
| Potassium Chloride | Potassium Chloride | 55 | 13 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 52 | 17 |
| Metformin Hcl Er | Metformin Hcl | 52 | 17 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | suppressed |
| Kerendia | Finerenone | 49 | suppressed |
| Folic Acid | Folic Acid | 48 | 11 |
| Loperamide | Loperamide Hcl | 48 | 11 |
| Nifedipine Er | Nifedipine | 46 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Tradjenta | Linagliptin | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 13 |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 25 |
| Halobetasol Propionate | Halobetasol Propionate | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 20 |
| Single Use Swab | Alcohol Antiseptic Pads | 38 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 36 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | 11 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | 11 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Clotrimazole | Clotrimazole | 26 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 15 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | 12 |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $826.38 · 35 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, EDARBI, ELIQUIS, FARXIGA, Kerendia, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Veozah, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error